
Opinion|Videos|October 14, 2024
Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC
Key Takeaways
- Urologists need oncologists to provide systemic therapy insights and manage immune-related adverse events in combination therapy.
- Oncologists rely on urologists for expertise in local disease management and patient selection for combination therapy.
Panelists discuss how urologists and oncologists must collaborate to improve outcomes for high-risk non–muscle-invasive bladder cancer (NMIBC) patients receiving combination therapy with PD-1/PD-L1 inhibitors and BCG, emphasizing the need for clear communication and coordinated care strategies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What do urologists need from oncologists, and vice versa, in improving outcomes for high-risk non–muscle-invasive bladder cancer patients for combination therapy with PD-1/PD-L1 inhibitors plus BCG?
Advertisement
Related to this article

This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.

The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.

Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.

Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.

Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Casdatifan shows activity across treatment settings in advanced ccRCC
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5



